Company logo

ENSC - Ensysce Biosciences, Inc.

NASDAQ -> Healthcare -> Biotechnology
La Jolla, United States
Type: Equity

ENSC price evolution
ENSC
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Current assets
Cash
Short term investments
Net receivables $0.28 $0.81 $0.44
Inventory
Total current assets $7.19 $11.66 $15.66
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $7.95 $12.37 $16.42
Current liabilities
Accounts payable $3.05 $0.96 $0.3
Deferred revenue
Short long term debt
Total current liabilities $8.25 $8.8 $16.48
Long term debt $0.14 $1.59 $4.44
Total noncurrent liabilities
Total debt
Total liabilities $8.44 $10.98 $24.3
Shareholders' equity
Retained earnings -$95.51 -$87.51 -$85.85
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Current assets
Cash $0.05 $1.06 $1.66
Short term investments
Net receivables $0.44 $0.02 $0.14 $0.17
Inventory
Total current assets $15.66 $0.23 $1.2 $1.92
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets $12.63 $195.31
Total investments
Total assets $16.42 $12.85 $196.51 $204.83
Current liabilities
Accounts payable $0.3 $0.26 $2.77 $0.43
Deferred revenue
Short long term debt
Total current liabilities $16.48 $0.26 $2.77 $0.44
Long term debt $4.44 $0.79 $0.57
Total noncurrent liabilities $13.8 $188.74
Total debt
Total liabilities $24.3 $14.06 $191.51 $7.44
Shareholders' equity
Retained earnings -$85.85 -$1.21 -$0.14 $2.09
Other shareholder equity
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue $0.21 $0.6
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $7.26 $5.41
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense -$0.04 -$0.02
Net income
Net income -$7.9 -$0.95
Income (for common shares)
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Revenue
Total revenue $3.53
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $23.4 $1.37 $3.33 $0.96
Operating income -$1.37 -$3.33
Income from continuing operations
EBIT
Income tax expense $0.24 $0.56 $0.55
Interest expense -$0.62 $3.64
Net income
Net income -$29.08 $4.31 -$1.07 $2.12
Income (for common shares)
(in millions $) 30 Jul 2022 1 May 2022 31 Jan 2022 29 Oct 2021
Net income -$19.11
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$4.47
Investing activities
Capital expenditures
Investments
Total cash flows from investing $0
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$0.66 -$0.39 $20.31 $11.13
Effect of exchange rate
Change in cash and equivalents -$8.53 -$3.82 $12.07 $6.65
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Net income $4.31 -$1.07
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$0.86 -$1.42
Investing activities
Capital expenditures
Investments
Total cash flows from investing $183.4 $11.85 $0.84
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $20.31 -$183.55 -$11.03 -$0.03
Effect of exchange rate
Change in cash and equivalents $12.07 -$1.01 -$0.6 -$0.43
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Quick ratio N/A